| Sep 27 |
Humacyte: Surprise PDUFA Delay, Low Cash, Excellent Product
|
| Sep 26 |
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024
|
| Sep 25 |
Exploring Three High Growth Tech Stocks in the United States
|
| Sep 25 |
Humacyte stock falls on plans to sell up to $50M shares to Lincoln Park
|
| Sep 24 |
Humacyte: Navigating The FDA Uncertainty And ATEV's Potential
|
| Sep 19 |
Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)
|
| Sep 3 |
Humacyte to Participate at Upcoming Investor Conferences in September
|
| Aug 27 |
Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program
|
| Aug 13 |
Humacyte, Inc. (HUMA) Q2 2024 Earnings Call Transcript
|
| Aug 13 |
Humacyte GAAP EPS of -$0.48 misses by $0.24
|
